A 56-year-old woman with type 2 diabetes mellitus and mild renal impairment (eGFR 55 mL/min/1.73 m²) undergoes right femoral nerve block for total knee arthroplasty. The anesthesiologist administers 25 mL of 0.75% ropivacaine under ultrasound guidance. Two hours postoperatively, the patient develops severe bradycardia (heart rate 32/min), hypotension (BP 78/48 mmHg), and loss of consciousness. Arterial blood gas shows severe metabolic acidosis (pH 7.08, HCO₃⁻ 12 mEq/L). What is the most likely precipitating factor for this presentation?

Explanation

## Clinical Diagnosis: Delayed Local Anesthetic Systemic Toxicity (LAST) ### Case Analysis **Key Point:** This patient has **delayed LAST** — a critical variant that occurs hours after injection, particularly in patients with renal impairment or hepatic dysfunction who cannot clear the local anesthetic. ### Risk Factors for LAST in This Patient | Risk Factor | Present? | Mechanism | |-------------|----------|----------| | **Renal impairment (eGFR 55)** | ✓ | Ropivacaine metabolites accumulate; reduced clearance | | **Diabetes mellitus** | ✓ | Impaired metabolism; autonomic neuropathy masks early signs | | **Dose: 25 mL of 0.75%** | ✓ | 187.5 mg ropivacaine; at upper limit for peripheral nerve block | | **Delayed onset (2 hours)** | ✓ | Suggests gradual systemic absorption or slow vascular uptake | | **Severe metabolic acidosis** | ✓ | Hallmark of advanced LAST; worsens cardiotoxicity | ### Ropivacaine Pharmacokinetics - **Metabolism:** Hepatic (CYP3A4, CYP1A2); metabolites cleared renally - **Half-life:** ~1.8–2.2 hours (normal renal function); **prolonged in renal impairment** - **Cardiotoxicity:** Less than bupivacaine but still significant, especially with acidosis - **Protein binding:** 94% (highly lipophilic) **High-Yield:** Renal impairment is a major risk factor for delayed LAST because metabolites (which retain some toxicity) accumulate and prolong the toxic window. ### Why Delayed Presentation Occurred ```mermaid flowchart TD A[Femoral nerve block<br/>187.5 mg ropivacaine]:::outcome --> B[Slow vascular uptake<br/>or microinjection]:::outcome B --> C[Gradual systemic absorption<br/>over 1-2 hours]:::outcome C --> D[Impaired renal clearance<br/>eGFR 55]:::action D --> E[Accumulation of active drug<br/>& metabolites]:::outcome E --> F[Delayed onset CNS/cardiac toxicity<br/>2 hours post-injection]:::urgent F --> G[Severe bradycardia, hypotension,<br/>metabolic acidosis, LOC]:::urgent ``` ### Clinical Features of Delayed LAST 1. **Cardiovascular predominance:** Bradycardia, hypotension (vs. early seizures in acute LAST) 2. **Severe metabolic acidosis:** pH 7.08 is life-threatening; acidosis worsens cardiotoxicity 3. **Loss of consciousness:** Indicates severe CNS depression 4. **Timing:** Hours after injection (not minutes as in acute intravascular injection) **Clinical Pearl:** Patients with renal impairment or diabetes may have **blunted early CNS signs** (tinnitus, restlessness) due to autonomic neuropathy, making delayed cardiac collapse the presenting feature. ### Management 1. **Immediate:** Lipid emulsion 1.5 mL/kg IV bolus, then 0.25 mL/kg/min infusion 2. **Airway:** Intubate; 100% oxygen 3. **Acidosis correction:** Sodium bicarbonate 1–2 mEq/kg IV (improves cardiac stability) 4. **Cardiac support:** Atropine for bradycardia; epinephrine if asystole (use small doses: 1 μg/kg) 5. **Monitoring:** Prolonged resuscitation (>1 hour); consider ECMO if refractory **Warning:** Do NOT use vasopressin, calcium channel blockers, or propofol — these worsen LAST outcomes.